Abstract Library

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,

#3466 Improving understanding of neuroendocrine tumors (NETs) – A key to improving patient outcomes

Introduction: The International Neuroendocrine Cancer Alliance (INCA) is a global umbrella organization advocating on behalf of neuroendocrine patients to improve time to diagnosis, care and research.

Conference:

Presenting Author: McDonnell M

Authors: McDonnell M, Kolarova T, van Genechten D, Gellerman E, Dureja S,

Keywords: neuroendocrine, awareness, education, improve, outcome, global,

#3217 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) - NET experts & NET healthcare

Introduction: SCAN assessed global delivery of healthcare to NET patients. This analysis provides a comparative perspective – Advanced Economies (AE) vs. Emerging and Developing Economies (EDE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McDonnell M

Authors: McDonnell M, Kolarova T, Bouvier C, Pavel M, Singh H,

Keywords: access, NET specialist, NET healthcare, challenges, global,

#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Yao J, Kolarova T, Goldstein G, Sissons M,

Keywords: Symptom burden,